用PREVENT方程比较SPRINT试验中强化与标准收缩压控制的初级预防效果
该研究对SPRINT试验中无基线心血管疾病的6554名参与者进行二次分析,按PREVENT方程10年总心血管风险分层(低/临界<7.5%、中7.5%-<20%、高≥20%),评估强化(<120 mmHg)与标准(<140 mmHg)收缩压治疗对主要复合终点及严重不良事件的相对和绝对效应。结果显示强化治疗的相对风险降低在各风险层间一致,但绝对风险差异从低/临界组的0.002到高风险组的0.024,提示PREVENT有助于识别从强化降压中获得显著绝对获益的人群。
要点
- 强化降压的相对获益在PREVENT各风险层间一致(交互P=0.68)。
- 4年绝对风险差异随风险升高而增大:低/临界0.002、中0.015、高0.024。
- 严重不良事件相对风险各层间无交互(P=0.44),中风险层HR 1.66(95%CI 1.24-2.24)。
核心结论
- 在无基线心血管疾病的SPRINT参与者中,强化与标准收缩压治疗的相对风险降低在PREVENT风险层间一致,但绝对风险差异从低/临界组到高风险组变化数倍。
研究设计与样本
- SPRINT试验的二次分析,纳入6554名无 prevalent CVD 且数据完整的参与者,按基线PREVENT 10年总心血管风险分为低/临界(<7.5%)、中(7.5%-<20%)、高(≥20%)三层。
- 参与者平均年龄65岁,37%女性,53%非西班牙裔白人,中位PREVENT 10年总心血管风险13%(Q1-Q3:9%-19%)。
- 比较强化(<120 mmHg)与标准(<140 mmHg)收缩压治疗对主要复合终点(心肌梗死、急性冠脉综合征、卒中、心力衰竭或心血管死亡)及治疗相关严重不良事件的影响。
- 中位随访3.86年。
主要发现
- 心血管事件HR:低/临界风险0.74(95%CI 0.33-1.66),中风险0.70(95%CI 0.52-0.93),高风险0.85(95%CI 0.60-1.20),交互P=0.68。
- 4年绝对风险差异:低/临界0.002,中0.015,高0.024。
- 严重不良事件HR:低/临界1.12(95%CI 0.53-2.38),中1.66(95%CI 1.24-2.24),高1.28(95%CI 0.87-1.87),交互P=0.44。
关键数值与推荐
- PREVENT 10年总心血管风险分层:低/临界<7.5%,中7.5%至<20%,高≥20%。
- 强化降压目标:收缩压<120 mmHg;标准降压目标:收缩压<140 mmHg。
临床怎么用
- 临床可使用PREVENT方程对无心血管疾病患者进行风险分层,以识别从强化收缩压控制中获得较大绝对获益的高风险人群。
- 强化降压的相对获益在各风险层中一致,但绝对获益随基线风险升高而增加,决策时应结合绝对风险差异。
- 需关注强化治疗相关的严重不良事件,尤其在中风险层观察到HR 1.66(95%CI 1.24-2.24)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Predicting Risk of Cardiovascular Disease Events (PREVENT) equations may provide more precise risk stratification than older calculators by incorporating estimated glomerular filtration rate, excluding race, and capturing total cardiovascular disease (CVD) events including heart failure. OBJECTIVES: The aim of this study was to quantify the relative and absolute benefits and harms of intensive vs standard systolic blood pressure (SBP) treatment by the new PREVENT risk levels. METHODS: A secondary analysis of SPRING (Systolic Blood Pressure Intervention Trial) was performed among participants without prevalent CVD and with complete data to calculate the baseline PREVENT 10-year risk for total CVD, which was categorized as low or borderline (<7.5%), intermediate (7.5% to <20%), and high (≥20%). Across these groups, the HRs and 4-year absolute risk differences were estimated for the effect of intensive (<120 mm Hg) vs standard (<140 mm Hg) SBP treatment on the primary composite outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or CVD death) and treatment-related serious adverse events. RESULTS: Of 6,554 SPRINT participants analyzed (mean age 65 years, 37% women, 53% non-Hispanic White), the median PREVENTbase 10-year risk for total CVD was 13% (Q1-Q3: 9%-19%). Respectively, 16%, 62%, and 22% were categorized as low or borderline, intermediate, and high risk. Over a median follow-up period of 3.86 years, the HRs for CVD events comparing intensive vs standard treatment were 0.74 (95% CI: 0.33-1.66) for low or borderline risk, 0.70 (95% CI: 0.52-0.93) for intermediate risk, and 0.85 (95% CI: 0.60-1.20) for high risk (P for interaction = 0.68). The 4-year absolute risk difference was 0.002 for low or borderline, 0.015 for intermediate, and 0.024 for high risk. Similarly, there was no evidence of interaction on the relative risk scale across PREVENT strata for serious adverse events with intensive vs standard treatment (low or borderline: HR: 1.12 [95% CI: 0.53-2.38]; intermediate: HR: 1.66 [95% CI: 1.24-2.24]; high: HR: 1.28 [95% CI: 0.87-1.87]; P for interaction = 0.44). CONCLUSIONS: Among SPRINT participants without baseline CVD, the relative risk reduction with intensive vs standard SBP treatment was consistent across PREVENT risk strata. However, the absolute risks varied several-fold from the low- or borderline-risk group to the high-risk group. These findings underscore the utility of PREVENT to identify those most likely to derive substantial absolute benefit from intensive SBP control for primary prevention.
引用
- Derington, Berchie, Greene, et al. Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT. J Am Coll Cardiol. 2025. PMID: 41125318. doi:10.1016/j.jacc.2025.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。